Table 2.
Baseline laboratory variables in the two treatment groups
| Variables | Citrate (n = 38) | Anticoagulant-free (n = 38) | p value |
|---|---|---|---|
| BUN, mg/dL | 67.8 (35.6, 98.1) | 65.0 (38.7, 86.0) | 0.755 |
| Cr, mg/dL | 3.2 (2.5, 4.4) | 3.8 (2.4, 6.2) | 0.104 |
| Sodium, mEq/L | 140.0±6.4 | 138.1±8.2 | 0.262 |
| Potassium, mEq/L | 4.5±1.1 | 4.3±1.0 | 0.591 |
| Bicarbonate, mEq/L | 14.0±4.8 | 13.4±5.3 | 0.604 |
| Lactate, mmol/L | 3.3 (1.5, 8.2) | 4.8 (2.6, 6.3) | 0.486 |
| Arterial pH | 7.3±0.1 | 7.3±0.1 | 0.732 |
| PaO2/FiO2 ratio | 300.0 (212.5, 397.5) | 266.3 (184.0, 415.8) | 0.721 |
| Hemoglobin, g/dL | 8.4±1.7 | 9.2±1.6 | 0.027 |
| Hematocrit (%) | 25.2±4.3 | 27.2±5.2 | 0.052 |
| Platelet, U/L | 85,000 (61,500, 257,000) | 88,000 (48,000, 220,000) | 0.839 |
| PTT, s | 32.8 (29.8, 44.6) | 38.1 (35.9, 49.0) | 0.112 |
| PT, s | 16.5 (14.4, 21.4) | 17.0 (14.2, 22.9) | 0.376 |
| INR ratio | 1.4 (1.3, 2.0) | 1.7 (1.4, 2.2) | 0.105 |
| iCa, mg/dL | 4.1±0.6 | 4.3±0.6 | 0.449 |
| Total bilirubin, mg/dL | 1.4 (0.5, 3.4) | 1.1 (0.7, 2.2) | 0.775 |
| Direct bilirubin, mg/dL | 1.2 (0.3, 2.8) | 0.9 (0.6, 2.0) | 0.996 |
| SGOT, U/L | 57.5 (34, 214) | 75 (37, 572) | 0.368 |
| SGPT, U/L | 29 (19, 65) | 43 (17, 180) | 0.275 |
| ALP, U/L | 84.0 (59, 126) | 87 (59, 132) | 0.903 |
Data are presented by mean ± SD for parametric data and median (IQR) for non-parametric data. Discrete outcomes were expressed as number of events and percentage. BUN, blood urea nitrogen; Cr, creatinine; PT, prothrombin time; PTT, partial thrombin time; INR, international normalized ratio; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvate transaminase; ALP, alkaline phosphatase.